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Targeting of the BRAFV600 mutation has proven a highly
effective treatment strategy for the subset of melanoma
carrying this mutation. However, the majority (~60%) of
patients with advanced melanoma do not carry this muta-
tion and are not targetable by selective BRAF inhibitors.
The rapidly evolving genetic landscape of melanoma has
revealed that the vast majority of non-V600 BRAF mutant
melanoma still express other genomic alterations that lead
to MAP kinase pathway activation. The most frequent of
these are activating mutations in the NRAS gene repre-
senting 1/3 of the non-V600 BRAF mutant melanoma or
15-20% overall. The other MAPkinase activating genetic
alteration include NF1 loss of function, MAP2K1, C-RAF,
K- or H-RAS, and alternate -non-V600 mutations in the
BRAF gene. Therefore MEK inhibitors, ERK inhibitors, or
even non-selective RAF inhibitors may represent effective
therapeutic interventions. Early results in the NRAS
mutant and non-NRAS or BRAF V600E mutant melanoma
demonstrate clinical activity but likely not as robust as
hoped. A trial with a MEK inhibitor (binmetinib) has
demonstrated an unconfirmed objective response rate of
approximately 20%. MEK inhibitors are also active against
non-NRAS, non-BRAF V600 mutant melanoma including
responses in those melanomas carrying mutations in
BRAF gene outside of V600 codon.
Genomic findings also demonstrate a high frequency of
dysregulation of cell cycle regulatory proteins including
genomic alterations in CDKN2A, CDK4, Cyclin D1, etc.
This finding suggests a role for CDK4/6 inhibitors in the
therapy of melanoma. Additionally, preclinical work has
demonstrated the effectiveness of the combination of
MEK inhibitors (trametinib, binimetinib) with CDK4/6
inhibitors (palbociclib, LEE011) in multiple mouse models
of NRAS mutant melanoma. New, selective, and more
effective CDK4/6 inhibitors have arrived in the clinic
including palbociclib and LEE011 to name several, Based
on this background clinical investigations have recently
begun in non-BRAF V600 mutant melanomas with combi-
nation MEK inhibitor and CDK4/6 inhibitor treatment.
While very early in their development, Binimetinib and
LEE011 has already produced objective clinical responses
in about 1/3 of NRAS mutant melanoma patients with
another 1/3 demonstrating clinical responses not meeting
RECIST 1.1 criteria. Most impressive is the rapid nature of
these responses and in some cases accompanying relief
from tumor-related symptoms. Early on some significant
toxicities have been observed and alternate schedules are
being explored. These regimens are also being evaluated
in the non-NRAS mutant, non BRAF V600 mutant mela-
nomas. As premature as these results are they still provide
excitement that targeting mutations other than BRAFV600
is feasible and may provide hope for additional therapeutic
options for the majority of melanoma patients.
Published: 15 January 2015
doi:10.1186/1479-5876-13-S1-K9
Cite this article as: Sosman: MEK + CDK4 a regimen for non-BRAF
V6000 melanoma. Journal of Translational Medicine 2015 13(Suppl 1):K9.
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, USA
Sosman Journal of Translational Medicine 2015, 13(Suppl 1):K9
http://www.translational-medicine.com/content/13/S1/K9
© 2015 Sosman; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
